#USA #NASDAQ #Atlanta #Alzamend Neuro #ALZN

Alzamend Neuro Regains Nasdaq Compliance

In a significant development for Alzamend Neuro, Inc. (Nasdaq: ALZN), the clinical-stage biopharmaceutical enterprise has been notified by Nasdaq that it has regained compliance with its listing standards. According to a compliance notice dated September 14, 2026, Alzamend managed to demonstrate a stockholders' equity exceeding the required minimum of $2.5 million. The company reported an impressive equity total of $5,802,680 in its Quarterly Report for the quarter ending July 31, 2026.

This good news comes after Alzamend faced a notification back in March 2026 indicating that it did not meet Nasdaq's minimum market value requirements for continued listing. In response, Alzamend submitted a plan to regain compliance, which was favorably received by Nasdaq, allowing the company a grace period until September 16, 2026, to rectify the situation.

Stephan Jackman, CEO of Alzamend, expressed satisfaction with the successful compliance regained, emphasizing the importance of maintaining their Nasdaq listing for the company's ongoing mission. Alzamend aims to focus on advancing its lead compound, AL001, through four Phase II clinical trials, carried out in partnership with Massachusetts General Hospital. The company has made noteworthy strides in its research, with the initial phase involving healthy human participants commencing in May 2025 and concluding in November 2025. Topline data from this trial was reported in March 2026, showing promise for ALS001 in treating various mental health issues.

Following the encouraging progress in the initial cohort, Alzamend launched a trial for participants with bipolar disorder in April 2026 and aims to sequentially initiate trials involving patients suffering from Alzheimer's disease, major depressive disorder, and post-traumatic stress disorder.

About Alzamend Neuro

Alzamend Neuro is dedicated to developing innovative therapies for complex mental health disorders, including Alzheimer's disease, bipolar disorder, major depressive disorder, and PTSD. The company is working with two promising candidates in its pipeline. The first, AL001, is a unique ionic cocrystal designed to enhance the delivery of lithium and improve safety compared to standard lithium treatments. Secondly, ALZN002 is a groundbreaking cell-based therapeutic vaccine aiming to rejuvenate the immune system's ability to clear beta-amyloid, a key protein associated with Alzheimer's disease. This next-generation approach offers potential advantages over existing therapies, including enhanced dosing frequency and cost-effectiveness compared to passive immunotherapies currently approved for use. Both drug candidates are exclusively licensed under royalty-bearing agreements from the University of South Florida Research Foundation, marking a significant step for Alzamend in the biopharmaceutical landscape.

Forward-Looking Statements

This announcement contains forward-looking statements as defined by the Securities Act of 1933 and the Securities Exchange Act of 1934. Such statements typically involve predictiveness and reference to future events or conditions. Phrasing that indicates this predictiveness includes terms such as "believes," "plans," "anticipates," and similar expressions that spotlight future outcomes rather than firm historical facts. Alzamend warns that these declarations are based on current assumptions, which are subject to various risks and uncertainties, and the company disclaims any obligation to update such statements in light of new findings or developments. Factors that could significantly affect Alzamend's actual results may be listed in its filings with the U.S. Securities and Exchange Commission, all of which are publicly accessible.

In conclusion, Alzamend's regained compliance with Nasdaq is a pivotal moment for the company as it enables it to refocus on its core mission—developing innovative treatments for mental health disorders that have long been unmet needs in medicine.